An interventional study of Doraldo-Castelletti scale in Migraine, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Istituto Auxologico Italiano · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in Migraine Disorders with a site in Italy — 37 open to participants now, 47 under way, 13 of them phase 3. Migraine Disorders · Italy.
Among the 115 studies in Migraine Disorders with a site in Italy, this one is the 31st largest by planned enrollment of the 73 interventional ones that give a count, is one of 9 that started in 2025, is one of 23 with no phase, reaches primary completion later than 37 of the 46 other live ones, and was the 113th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →37 of the 115 studies in Migraine Disorders with a site in Italy are open now. Recruiting first, the newest first:
Istituto per la Ricerca e l'Innovazione Biomedica · Sites in Italy
Ages 18–75 · Healthy volunteers
University of Roma La Sapienza · Sites in Italy
Ages 18–65
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Sites in Italy
Ages 18–65
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Pfizer · Sites in Italy, United States, Argentina and 12 more countries
Ages 18–45 · Women only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 439 is above the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 315 across the 73 interventional studies, 108 across the 42 observational. Of the 58 that completed or were terminated, 26 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 115 have an industry lead sponsor. The 10 most frequent:
Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.
Istituto Auxologico Italiano has 1 study filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
15 of the studies in Migraine Disorders with a site in Italy that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 15 to your calendar (.ics) → With an account.
Among the 115 studies in Migraine Disorders with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Migraine is the leading cause of disability worldwide among people aged 15 to 49. Although therapies targeting the CGRP pathway have improved the management of the condition, there are large groups of patients who do not respond to medications or for whom these are contraindicated. In this context, non-pharmacological therapies such as physical therapy play a crucial role.
The scientific literature highlights a strong link between migraine and cervical disorders:
Despite the proven utility of physical therapy for the prevention and treatment of migraine (as demonstrated by validated physical tests and standardized questionnaires such as the NDI, HDI, and HIT-6), musculoskeletal screening is not routinely included in neurological examinations. Neurologists in headache centers generally lack the time and specific manual skills required to perform a thorough physical assessment of the cervical spine.
There is therefore a lack of a rapid and effective screening tool that serves as a "bridge" between neurology and rehabilitation.
The primary objective of the MIGSKA study is to evaluate the performance of the Doraldo-Castelletti scale in assessing the clinical need and motivation of patients with migraine to undergo physical therapy. The study will also assess the utility of this scale as a decision-making tool for neurologists in referring appropriate patients to physical therapists.
To address this gap in clinical practice, the study analyzes the Doraldo-Castelletti scale. The adoption of this tool aims to:
Migraine is the leading cause of disability worldwide among people aged 15 to 49. Although therapies targeting the CGRP pathway have improved the management of the condition, there are large groups of patients who do not respond to medications or for whom these are contraindicated. In this context, non-pharmacological therapies such as physical therapy play a crucial role.
The scientific literature highlights a strong link between migraine and cervical disorders:
Despite the proven utility of physical therapy for the prevention and treatment of migraine (as demonstrated by validated physical tests and standardized questionnaires such as the NDI, HDI, and HIT-6), musculoskeletal screening is not routinely included in neurological examinations. Neurologists in headache centers generally lack the time and specific manual skills required to perform a thorough physical assessment of the cervical spine.
There is therefore a lack of a rapid and effective screening tool that serves as a "bridge" between neurology and rehabilitation.
The primary objective of the MIGSKA study is to evaluate the performance of the Doraldo-Castelletti scale in assessing the clinical need and motivation of patients with migraine to undergo physical therapy. The study will also assess the utility of this scale as a decision-making tool for neurologists in referring appropriate patients to physical therapists.
To address this gap in clinical practice, the study analyzes the Doraldo-Castelletti scale. The adoption of this tool aims to:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Migraine patients are the targeted population for administration of the Doraldo-Castelletti scale during a neurological visit
Other: Doraldo-Castelletti scale
During a routine neurological examination, the physician administers the Doraldo-Castelletti scale to the migraine patient. The scale consists of 10 multiple choice questions.
Score of the Doraldo-Castelletti scale
Scale consisting of 10 multiple choice questions; Minimum score = 0; Maximum score = 13
Time frame: At baseline
Proportion of patients referred to physiotherapist
Proportion of patients referred to physiotherapist on the basis of the score of the Doraldo-Castelletti scale
Time frame: At baseline
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Oct 2027, 22 months after the start.
Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 22 months is above that.
Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Auxologico Italiano →